腹腔免疫化疗对晚期结肠癌癌性腹水患者IL-6及IL-10影响

目的：探讨腹腔内免疫化疗前后晚期结肠癌癌性腹水患者血清IL－6及IL－10水平的变化及其意义。方法：采用酶联免疫法测定治疗前、治疗后1周及治疗后4周患者外周血清中IL－6及IL－10水平，并与正常对照组比较。结果：晚期结肠癌癌性腹水患者血清IL－6和IL－10水平较正常组明显升高。腹腔内免疫化疗治疗晚期结肠癌癌性腹水患者1周后大部分患者外周血清中IL－6及IL－10水平有所下降。四周后所有患者的IL－6和IL－10均有下降。且第1周后IL－6及IL－10水平有否变化与免疫化疗是否有效有明显关系。结论：腹腔内免疫化疗是治疗晚期结肠癌癌性腹水较为有效的方法。同时，早期监测外周血清中IL－6和IL－10水平对腹腔内免疫化疗的疗效有预测功能。

The Effects of Intraperitoneal Immunochemotherapy on IL-6 and IL-10 Level in Patients with Advanced Colon Cancer with Ascites

Objective: To study the effects of intraperitoneal immunochemotherapy on IL - 6 and IL - 10 level of advanced colon cancer patients with ascites. Methods: Before and after treatment, serum levels of IL -6 and IL -10 were observed by ELISA assay in 38 patients and compared with that in the control group. Results: The serum level of IL- 6 and IL- 10 of advanced colon cancer patients with ascites were higher than those of the control group. Serum level of IL - 6 and IL - 10 of most patients were decreased after first week of intraperitoneal immunochemotherapy and serum level of IL - 6 and IL - 10 were decreased in all patients after four weeks. And the change of serum level of IL - 6 and IL - 10 after first week treatment were correlated with effects of intraperitoeal immunochemotherapy. Conclusion: Intraperitoeal immunochemotherapy is an effective way for treat advanced colon cancer with ascites. Early monitoring serum level of IL - 6 and IL - 10 can predict the effect of intraperitoeal immunochemotherapy.